Filing Details
- Accession Number:
- 0001415889-25-002955
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-02-04 16:35:06
- Reporting Period:
- 2025-02-03
- Filing Date:
- 2025-02-04
- Accepted Time:
- 2025-02-04 16:35:06
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1671858 | Ars Pharmaceuticals Inc. | SPRY | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1551891 | Laura Shawver | C/O Ars Pharmaceuticals, Inc. 11682 El Camino Real, Suite 120 San Diego CA 92130 | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2025-02-03 | 9,064 | $3.15 | 219,410 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2025-02-03 | 40,936 | $4.85 | 260,346 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2025-02-03 | 50,000 | $12.31 | 210,346 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2025-02-03 | 9,064 | $0.00 | 9,064 | $3.15 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2025-02-03 | 40,936 | $0.00 | 40,936 | $4.85 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2032-05-01 | No | 4 | M | Direct | |
| 124,064 | 2032-01-31 | No | 4 | M | Direct |
Footnotes
- The shares reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2024.
- The weighted average sale price for the transaction reported was $12.3113 and the range of prices were between $11.9732 and $12.76. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- Immediately exercisable.
Billionaire Hedge Funds
